ArticleInternational journal of women's health2026
Antihypertensive Drug Target Genes and Epithelial Ovarian Cancer Risk: A Two-Sample Mendelian Randomization Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Findings on the relationship between the use of antihypertensive drugs and the risk of epithelial ovarian cancer (EOC) have been inconsistent. We performed a two-sample Mendelian randomization (MR) using gene expression of target genes as genetic proxies for antihypertensive drug action to interrogate this. Methods: Genetic instruments for expression of antihypertensive medication target genes were identified with expression quantitative trait loci (eQTLs) in blood. Summary statistics for overall EOC and high-grade serous ovarian cancer (HGSOC) were obtained from genome wide association study (GWAS) datasets. The inverse variance weighted (IVW) method was used as the primary model. Sensitivity analysis based on different statistical assumptions was used to evaluate whether the results were robust. Bonferroni Corrections were used to identify significant associations due to multiple testing. Results: CACNA2D3 is a target of calcium channel blockers (CCBs). The MR analysis demonstrated that CACNA2D3 gene expression was associated with a lower risk of overall EOC (IVW OR = 0.919, 95% CI: 0.881-0.958, P = 7.186 × 10 Conclusion: This study supports potential protective effects of genetically proxied CACNA2D3 expression on EOC risk, which may be consistent with the beneficial effects of CCBs, while further validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.